Photo taken from Benjamin Besse/Twitter
May 23, 2024, 14:25
Benjamin Besse: Should we infuse IO in the morning?
Benjamin Besse, Head of Clinical Research on Gustave Roussy, shared on X:
“Should we infuse IO in the morning? Intriguing work just published: Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. .
We may need to analyze timing of IO infusion in phase III trials to guide us in our daily clinic.”
Read further.
Source: Benjamin Besse/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 09:04
Dec 22, 2024, 07:59
Dec 22, 2024, 07:55
Dec 22, 2024, 07:44